View ValuationImpediMed 将来の成長Future 基準チェック /26ImpediMedは、40.8%と29.4%でそれぞれ年率40.8%で利益と収益が成長すると予測される一方、EPSはgrowで65.3%年率。主要情報40.8%収益成長率65.30%EPS成長率Medical Equipment 収益成長13.5%収益成長率29.4%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日12 May 2026今後の成長に関する最新情報Breakeven Date Change • Aug 18No longer forecast to breakevenThe 3 analysts covering ImpediMed no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$5.04m in 2027. New consensus forecast suggests the company will make a loss of AU$2.53m in 2027.Breakeven Date Change • Aug 29Forecast to breakeven in 2027The 2 analysts covering ImpediMed expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$23.7m in 2027. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Breakeven Date Change • Jul 30Forecast to breakeven in 2026The 4 analysts covering ImpediMed expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$1.95m in 2026. Average annual earnings growth of 54% is required to achieve expected profit on schedule.Breakeven Date Change • Feb 03No longer forecast to breakevenThe 3 analysts covering ImpediMed no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$3.15m in 2026. New consensus forecast suggests the company will make a loss of AU$2.18m in 2026.Breakeven Date Change • May 30No longer forecast to breakevenThe 4 analysts covering ImpediMed no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$891.8k in 2025. New consensus forecast suggests the company will make a loss of AU$377.6k in 2025.Breakeven Date Change • Apr 27No longer forecast to breakevenThe 3 analysts covering ImpediMed no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$2.63m in 2024. New consensus forecast suggests the company will make a loss of AU$6.03m in 2024.すべての更新を表示Recent updatesBoard Change • May 20High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Janelle Delaney is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • May 06+ 1 more updateImpediMed Limited has completed a Follow-on Equity Offering in the amount of AUD 13.2 million.ImpediMed Limited has completed a Follow-on Equity Offering in the amount of AUD 13.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 300,000,000 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,020,000,000 Price\Range: AUD 0.01 Transaction Features: Subsequent Direct Listingお知らせ • Apr 08+ 1 more updateImpediMed Limited Announces Chief Executive Officer ChangesImpediMed Limited announced the appointment of Erik Anderson as Chief Executive Officer. Anderson, who joined the company's Board of Directors in February 2026, succeeds Dr. Parmjot Bains. His appointment is effective April 7, 2026. Anderson's appointment comes as ImpediMed's business gains momentum with its Breast Cancer Related Lymphedema (BCRL) business. The Board determined that the next phase of growth requires a step change in commercial execution, particularly in the United States. Anderson's appointment reflects a focus on accelerating revenue growth, expanding health system adoption, managing costs, and advancing the company toward cash flow break-even and long-term value creation. Anderson brings to ImpediMed extensive commercial leadership experience in the US medical technology sector. Most recently, he served as President of the Breast and Skeletal Health Division at Hologic Inc. . During his tenure at Hologic, he led a large, multi-franchise commercial organization and grew one of the company's largest business units—a $1.6+ billion global franchise. He also brings deep expertise in healthcare delivery, including hospital sales, clinical adoption, and reimbursement, along with strong relationships across health systems and key stakeholders aligned with ImpediMed's growth priorities in BCRL, body composition, and heart health. With this experience, Anderson is well-positioned to lead ImpediMed's next phase of growth, expanding sales and distribution across U.S. health systems. Bains will continue in an advisory role through June 30, 2026, to support a smooth leadership transition.お知らせ • Jan 27ImpediMed Limited to Report Q2, 2026 Results on Jan 29, 2026ImpediMed Limited announced that they will report Q2, 2026 results on Jan 29, 2026Board Change • Dec 24High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Janelle Delaney is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Oct 24ImpediMed Limited to Report Q1, 2026 Results on Oct 30, 2025ImpediMed Limited announced that they will report Q1, 2026 results on Oct 30, 2025お知らせ • Sep 19ImpediMed Limited, Annual General Meeting, Nov 18, 2025ImpediMed Limited, Annual General Meeting, Nov 18, 2025.Reported Earnings • Aug 29Full year 2025 earnings released: AU$0.012 loss per share (vs AU$0.01 loss in FY 2024)Full year 2025 results: AU$0.012 loss per share (further deteriorated from AU$0.01 loss in FY 2024). Revenue: AU$12.7m (up 23% from FY 2024). Net loss: AU$23.2m (loss widened 17% from FY 2024). Revenue is forecast to grow 48% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Breakeven Date Change • Aug 18No longer forecast to breakevenThe 3 analysts covering ImpediMed no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$5.04m in 2027. New consensus forecast suggests the company will make a loss of AU$2.53m in 2027.お知らせ • Jul 16ImpediMed Limited to Report Q4, 2025 Results on Jul 31, 2025ImpediMed Limited announced that they will report Q4, 2025 results on Jul 31, 2025お知らせ • Apr 17ImpediMed Limited to Report Q3, 2025 Results on Apr 30, 2025ImpediMed Limited announced that they will report Q3, 2025 results on Apr 30, 2025お知らせ • Jan 28ImpediMed Limited to Report Q2, 2025 Results on Jan 31, 2025ImpediMed Limited announced that they will report Q2, 2025 results on Jan 31, 2025Board Change • Dec 24Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. 2 independent directors (4 non-independent directors). Independent Non-Executive Director Janelle Delaney is the most experienced director on the board, commencing their role in 2023. Independent Non-Executive Chair Christine Emmanuel-Donnelly was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Oct 15ImpediMed Limited to Report Q1, 2025 Results on Oct 22, 2024ImpediMed Limited announced that they will report Q1, 2025 results on Oct 22, 2024お知らせ • Sep 27ImpediMed Limited, Annual General Meeting, Nov 19, 2024ImpediMed Limited, Annual General Meeting, Nov 19, 2024.Recent Insider Transactions • Sep 03Board Member recently bought AU$73k worth of stockOn the 30th of August, Andrew Grant bought around 1m shares on-market at roughly AU$0.073 per share. This transaction increased Andrew's direct individual holding by 3x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$544k more in shares than they have sold in the last 12 months.Reported Earnings • Aug 30Full year 2024 earnings released: EPS: AU$0 (vs AU$0.011 loss in FY 2023)Full year 2024 results: EPS: AU$0 (improved from AU$0.011 loss in FY 2023). Revenue: AU$10.3m (down 9.0% from FY 2023). Net loss: AU$19.8m (loss narrowed 3.6% from FY 2023). Revenue is forecast to grow 50% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.Breakeven Date Change • Aug 29Forecast to breakeven in 2027The 2 analysts covering ImpediMed expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$23.7m in 2027. Average annual earnings growth of 59% is required to achieve expected profit on schedule.お知らせ • Aug 23ImpediMed Limited to Report Fiscal Year 2024 Results on Aug 29, 2024ImpediMed Limited announced that they will report fiscal year 2024 results Pre-Market on Aug 29, 2024Breakeven Date Change • Jul 30Forecast to breakeven in 2026The 4 analysts covering ImpediMed expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$1.95m in 2026. Average annual earnings growth of 54% is required to achieve expected profit on schedule.お知らせ • Jul 22+ 3 more updatesImpediMed Limited Appoints Parmjot Bains as CEO on an ongoing basisAs announced in November 2023, Dr. Parmjot Bains, CEO and Managing Director commenced in their roles in an interim capacity. The Board of ImpediMed Limited confirmed the appointment of Dr. Bains as Chief Executive Officer on an ongoing basis. In the 6-month period in their interim roles, Dr. Bains has implemented a number of significant changes across the business to ensure the Company is in the best position to achieve growth and profitability and ensure all patients at risk of cancer related lymphedema can access ImpediMed's unique technology.お知らせ • Jun 08ImpediMed Limited Appoints Fiona Bones as A Non-Executive DirectorThe Board of ImpediMed Limited announced the appointment of Ms Fiona Bones as a non-Executive Director of the Company, effective 07 June 2024. Ms Bones is currently VP of Finance, International Controller at Google and has worked at Google for over 20 years. Ms Bones is a Fellow of the Association of Chartered Certified Accountants, UK and Ireland and brings global experience in finance, corporate governance, and systems transformation.New Risk • Jun 04New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$149.7m (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$8.1m net loss in 2 years). Market cap is less than US$100m (AU$149.7m market cap, or US$99.4m).Recent Insider Transactions • May 15Independent Non-Executive Director recently bought AU$50k worth of stockOn the 8th of May, Janelle Delaney bought around 634k shares on-market at roughly AU$0.079 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth AU$100k. Insiders have collectively bought AU$883k more in shares than they have sold in the last 12 months.お知らせ • Apr 20ImpediMed Limited to Report Q3, 2024 Results on Apr 30, 2024ImpediMed Limited announced that they will report Q3, 2024 results on Apr 30, 2024お知らせ • Apr 11ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual MeetingImpediMed announced that it will present new results from a breast cancer-related lymphedema study during a poster session at the American Society of Breast Surgeons (ASBrS) Annual Meeting in Orlando, FL on April 12, 2024. The study, titled "Timing of Breast Cancer-related Lymphedema Development Over Three Years: Observations from a Large, Prospective Randomized Screening Trial," revealed that patients at risk of developing breast cancer related lymphedema (BRCL) should continue to be monitored for three years following the completion of cancer treatment, as patients could trigger at any time over this period. The results are part of PREVENT, the largest randomized control trial to assess lymphedema prevention, in 1200 women, which monitored progression to BCRL following intervention for BCRL assessed by both bioimpedance spectroscopy (BIS) and a tape measure, demonstrating lower progression to chronic lymphedema with early detection using BIS and intervention versus using tape measure. Lymphedema, a common consequence of cancer treatment, poses significant challenges in healthcare. According to the American Cancer Society 58% of cancer patients diagnosed with breast cancer, melanoma, or pelvic area cancers are at risk for developing limb lymphedema, and over 80% of breast cancer patients are at risk. ImpediMed has the only FDA-cleared BIS technology for the clinical assessment of lymphedema. The Company's SOZO® Digital Health Platform is broadly accepted and recognized for effective and accurate screening of lymphedema, with US payors now providing coverage for over 140 million covered lives. The PREVENT trial is a pivotal study and the largest randomized controlled trial to assess lymphedema prevention. The study enrolled 1,200 patients across 10 trial sites in the US and Australia, involving 13 hospitals, including Vanderbilt University, Mayo Clinic and MD Anderson. The trial was conducted over six and a half years and patients were followed for up to three years, with the primary aim to determine if early intervention in patients with subclinical detection of extracellular fluid accumulation via bioimpedance spectroscopy results in a lower rate of lymphedema progression versus the rate when tape measure is used for subclinical detection. The manuscript is published in Lymphatic Research and Biology. The results of the trial demonstrated that patients with early detection with L-Dex™ technology and at-home intervention with compression garments resulted in a 7.9% rate of chronic lymphedema compared to a 19.2% rate of chronic lymphedema using tape measure. The difference is statistically significant (p=0.016) as well as being clinically significant for patients and clinicians. This represents an absolute reduction of 11.3% and relative reduction of 59% in lymphedema progression at three years.Recent Insider Transactions • Mar 28Independent Non-Executive Director recently bought AU$100k worth of stockOn the 25th of March, Janelle Delaney bought around 1m shares on-market at roughly AU$0.087 per share. This transaction amounted to 54% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$905k more in shares than they have sold in the last 12 months.Recent Insider Transactions • Mar 02Independent Non-Executive Director recently bought AU$90k worth of stockOn the 29th of February, Andrew Grant bought around 230k shares on-market at roughly AU$0.39 per share. This transaction increased Andrew's direct individual holding by 3x at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth AU$135k. Insiders have collectively bought AU$898k more in shares than they have sold in the last 12 months.Breakeven Date Change • Feb 03No longer forecast to breakevenThe 3 analysts covering ImpediMed no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$3.15m in 2026. New consensus forecast suggests the company will make a loss of AU$2.18m in 2026.Board Change • Feb 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Janelle Delaney is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Jan 23ImpediMed Limited to Report First Half, 2024 Results on Feb 27, 2024ImpediMed Limited announced that they will report first half, 2024 results on Feb 27, 2024Recent Insider Transactions • Dec 19Independent Non-Executive Director recently bought AU$135k worth of stockOn the 14th of December, Janelle Delaney bought around 942k shares on-market at roughly AU$0.14 per share. This transaction increased Janelle's direct individual holding by 14x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$814k more in shares than they have sold in the last 12 months.お知らせ • Nov 20+ 2 more updatesImpediMed Limited Announces CFO ChangesImpediMed Limited announced leadership and Board changes to drive growth and manage costs. When elected, the Board announced a review of ImpediMed's strategy to ensure it was maximising the potential opportunities to transition to a high growth and profitable business. To date, the Board has considered the Company's operational readiness, approach to execution and cost structure. The review identified a very capable core management team, a distinctive product portfolio and an undeniable opportunity. However, more is needed to deliver robust execution and control costs. Given these challenges and the strong endorsement for change from ImpediMed shareholders at the recent General Meeting, the Board has determined that action now is appropriate. Tim Cruickshank has stepped down as CFO and the Board is discussing transition arrangements with him. Chair McGregor Grant assumes the responsibilities of CFO effective immediately, in an interim capacity and will be an Executive Chairman. The Chair, McGregor Grant will work closely with Dr. Bains as CFO, with a clear focus on managing costs. managing costs. For the last 12 years Mr. Grant was CFO and company Secretary of Nanosonics Limited. As well as leading financial strategy, Mr. Grant played a key role in developing and implementing corporate strategy. He was also responsible for operational functions including IT, legal and facilities management. During Mr. Grant's tenure at Nanosonics revenue grew from $2 million to $166 million. Together, Dr. Bains and Mr. Grant have extensive strategic, sales & marketing, financial and operational experience in high growth MedTech/healthcare businesses and will ensure stability and continuity of the business' operations. The Board recognises the significant talent within the senior management team, and Dr. Bains and Mr. Grant look forward to working closely with them to ensure the entire ImpediMed team remains focused on execution. Dr. Bains and Mr. Grant will also work closely with the management team to more deeply examine the Company's strategic and operational plans and its cost base to maximise the commercial opportunity and deliver value to its shareholders. Dr. Bains and Mr. Grant have been appointed to their roles in an interim capacity, which is expected to be in place for a period of up to six months while they assess the requirements of the business.お知らせ • Oct 24ImpediMed Limited to Report Q1, 2024 Results on Oct 31, 2023ImpediMed Limited announced that they will report Q1, 2024 results on Oct 31, 2023お知らせ • Oct 12ImpediMed Limited, Annual General Meeting, Nov 30, 2023ImpediMed Limited, Annual General Meeting, Nov 30, 2023, at 10:01 E. Australia Standard Time.Board Change • Oct 05High number of new directorsThere are 8 new directors who have joined the board in the last 3 years. Director McGregor Grant was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Sep 27ImpediMed Limited Announce the Appointment of Steven Chen as Chief Medical OfficerImpediMed Limited announced the appointment of Steven Chen, MD, MBA as Chief Medical Officer effective 26 September 2023. Dr. Chen is a board-certified surgical oncologist who brings strong business acumen and extensive leadership experience in cancer care and the healthcare industry. Dr. Chen's previous leadership and experience: Chief Medical Officer of Avelas Biosciences, a clinical stage drug-device company dedicated to improving cancer care. Chief of Breast Surgery, University of California Davis Medical Center. Associate Program Director of the surgical oncology training program at City of Hope National Medical Center, Duarte, California. Past President, American Society of Breast Surgeons (ASBrS). Clinical training at the John Wayne Cancer Institute, the University of Michigan and the Center for Health Care Economics. Over 70 publications and 5,000 citations. The University of California Davis, the City of Hope, and the University of Michigan are members of the National Comprehensive Cancer Network (NCCN®). Most recently, Dr. Chen served as the Chief Medical Officer of Avelas, a clinical stage drug-device company dedicated to improving cancer care. There, he successfully oversaw their lead asset through Investigational New Drug (IND) application and first in human studies through pivotal trials and established the company's clinical strategy to support commercialisation and reimbursement. Previously, Dr. Chen served as the Chief of Breast Surgery at UC Davis Medical Center, followed by a position as an Associate Professor of Surgery and as the Associate Program Director of the surgical oncology training program at City of Hope National Medical Center in Duarte, California. He is a past President of the American Society of Breast Surgeons and serves or served on committees for a number of professional societies including the American Medical Association, the Society of Surgical Oncology, and the American College of Surgeons. Dr. Chen is a practicing surgeon in San Diego, California and the Director of Surgical Oncology at OasisMD. Dr. Chen received his medical degree and completed general surgery and critical care residencies at the University of Michigan, followed by a surgical oncology fellowship at the John Wayne Cancer Institute. Dr. Chen also obtained his master's in business administration at the University of Michigan's Ross School of Business.Reported Earnings • Aug 31Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.012 loss in FY 2022)Full year 2023 results: AU$0.01 loss per share. Revenue: AU$11.3m (up 7.4% from FY 2022). Net loss: AU$20.5m (loss widened 3.3% from FY 2022). Revenue is forecast to grow 55% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia.お知らせ • Jul 17ImpediMed Limited to Report Q4, 2023 Results on Jul 24, 2023ImpediMed Limited announced that they will report Q4, 2023 results on Jul 24, 2023お知らせ • Jul 06ImpediMed Limited Appoints Daniel Sharp as DirectorImpediMed Limited appointed Mr. Daniel Sharp as director, date of appointment is July 1, 2023.Recent Insider Transactions • Jun 28Executive Director recently bought AU$144k worth of stockOn the 20th of June, David Anderson bought around 920k shares on-market at roughly AU$0.16 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth AU$158k. Insiders have collectively bought AU$1.0m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Jun 14Independent Non-Executive Chairman recently bought AU$82k worth of stockOn the 6th of June, Donald Williams bought around 500k shares on-market at roughly AU$0.16 per share. This transaction amounted to 7.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Donald has been a buyer over the last 12 months, purchasing a net total of AU$273k worth in shares.Breakeven Date Change • May 30No longer forecast to breakevenThe 4 analysts covering ImpediMed no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$891.8k in 2025. New consensus forecast suggests the company will make a loss of AU$377.6k in 2025.Recent Insider Transactions • Apr 22MD, CEO & Director recently bought AU$52k worth of stockOn the 20th of April, Richard Valencia bought around 410k shares on-market at roughly AU$0.13 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth AU$64k. Richard has been a buyer over the last 12 months, purchasing a net total of AU$170k worth in shares.Recent Insider Transactions • Mar 31MD, CEO & Director recently bought AU$54k worth of stockOn the 27th of March, Richard Valencia bought around 400k shares on-market at roughly AU$0.13 per share. This transaction amounted to 40% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth AU$64k. Richard has been a buyer over the last 12 months, purchasing a net total of AU$118k worth in shares.Recent Insider Transactions • Mar 08MD, CEO & Director recently bought AU$64k worth of stockOn the 6th of March, Richard Valencia bought around 1m shares on-market at roughly AU$0.064 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Richard's only on-market trade for the last 12 months.Reported Earnings • Feb 25First half 2023 earnings released: AU$0.01 loss per share (vs AU$0.006 loss in 1H 2022)First half 2023 results: AU$0.01 loss per share (further deteriorated from AU$0.006 loss in 1H 2022). Revenue: AU$5.66m (up 8.8% from 1H 2022). Net loss: AU$10.8m (loss widened 21% from 1H 2022). Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.お知らせ • Jan 24ImpediMed Limited to Report Q2, 2023 Results on Jan 30, 2023ImpediMed Limited announced that they will report Q2, 2023 results on Jan 30, 2023Board Change • Nov 17Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Bob Graham was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Nov 01Executive Director & Interim CEO recently bought AU$164k worth of stockOn the 28th of October, David Anderson bought around 2m shares on-market at roughly AU$0.094 per share. This transaction amounted to 89% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was David's only on-market trade for the last 12 months.Board Change • Oct 29Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Bob Graham was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 30Full year 2022 earnings released: AU$0.01 loss per share (vs AU$0.017 loss in FY 2021)Full year 2022 results: AU$0.01 loss per share (up from AU$0.017 loss in FY 2021). Revenue: AU$10.6m (up 26% from FY 2021). Net loss: AU$19.9m (loss narrowed 4.0% from FY 2021). Over the next year, revenue is forecast to grow 84%, compared to a 14% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.Board Change • Jul 28Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Bob Graham was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Breakeven Date Change • Apr 27No longer forecast to breakevenThe 3 analysts covering ImpediMed no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$2.63m in 2024. New consensus forecast suggests the company will make a loss of AU$6.03m in 2024.お知らせ • Mar 07New Bone Data Showing Strong Correlation Between ImpediMed's SOZO and DXA in Cancer Patients Presented At 39Th Annual Miami Breast Cancer ConferenceImpediMed Limited announced a poster showing strong correlation between ImpediMed's SOZO® Digital Health Platform and dual x-ray absorptiometry (DXA) for assessing bone mineral content in cancer patients was presented at the 39th Annual Miami Breast Cancer Conference on 3-6 March 2022 in Miami Beach, Florida, USA. The Miami Breast Cancer Conference draws leaders in breast cancer care for in-depth discussions about current topics and technologies. The poster is available to registered attendees in-person and online. Abstracts will be published online following the conference in the journal Oncology. The poster titled "The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device" demonstrated strong correlation between skeletal muscle mass (SMM) collected using SOZO and bone mineral content (BMC) collected using DXA in three groups: There are 16.9 million cancer survivors in the US and approximately 32 million worldwide. The majority of survivors are women with early-stage breast cancers and men with nonmetastatic prostate cancers. These patients frequently receive hormonal manipulation therapies that can significantly impact their bone mineral content. These patients have a higher risk of bone fractures potentially leading to hospitalisation and death. Multiple studies have shown a strong correlation between SMM and bone suggesting that a SOZO reading can provide a simple, quick, and reproducible estimate of BMC. Expanding the use of SOZO to help care for cancer patients is central to ImpediMed's growth strategy in oncology. Lymphoedema provides a strong entry point for the adoption of SOZO into oncology practices and remains the Company's key focus in the short term. Over the medium term, developing new broader oncology indications creates the opportunity to expand through demand for additional SOZO devices and adding new licenses to existing devices. Bone is one of a number of potential indications on ImpediMed's oncology product roadmap. Several large corporate accounts, as well as some prestigious institutions, have expressed an interest in the co-development of these potential indications with the goal of benefiting their cancer patients and improving health economics. The Company has initiated some small-scale clinical investigations and is currently assessing the opportunities. More information will be provided as they progress.Breakeven Date Change • Mar 05No longer forecast to breakevenThe 4 analysts covering ImpediMed no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$2.63m in 2024. New consensus forecast suggests the company will make a loss of AU$4.12m in 2024.Reported Earnings • Mar 01First half 2022 earnings: EPS in line with expectations, revenues disappointFirst half 2022 results: AU$0.006 loss per share (up from AU$0.01 loss in 1H 2021). Revenue: AU$5.20m (up 45% from 1H 2021). Net loss: AU$8.92m (loss narrowed 14% from 1H 2021). Revenue missed analyst estimates by 2.2%. Over the next year, revenue is forecast to grow 90%, compared to a 19% growth forecast for the industry in Australia. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Buying Opportunity • Feb 15Now 22% undervaluedOver the last 90 days, the stock is up 2.9%. The fair value is estimated to be AU$0.23, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% per annum over the last 3 years. Earnings per share has grown by 44% per annum over the last 3 years.Breakeven Date Change • Sep 23Forecast to breakeven in 2024The 3 analysts covering ImpediMed expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$100.0k in 2024. Average annual earnings growth of 61% is required to achieve expected profit on schedule.お知らせ • Aug 31FDA Grants Breakthrough Device Designation for ImpediMed's SOZO Digital Health Platform for Renal FailureImpediMed Limited announced that the SOZO Digital Health Platform was designated a Breakthrough Device by the Food and Drug Administration (FDA) for a proposed indication in renal failure. Using bioimpedance spectroscopy, the SOZO® Digital Health Platform aims to provide clinicians with a more precise measure of fluid volume to be removed from a renal failure patient during dialysis. The current standard-of-care method to measure the accumulation of fluid in kidney failure patients utilizes weight scales. These scales cannot account for changes in body composition, with muscle loss being a common side effect of end-stage renal disease patients. The potential for SOZO® to address this deficiency was paramount in the FDA awarding its Breakthrough Designation to the SOZO® Digital Health Platform. The Breakthrough Device Designation is granted when a device meets several criteria, including providing for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions.Reported Earnings • Aug 26Full year 2021 earnings released: AU$0.02 loss per share (vs AU$0.036 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: AU$8.41m (up 47% from FY 2020). Net loss: AU$20.7m (loss narrowed 3.1% from FY 2020). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.お知らせ • Jun 08Impedimed Announces Next Generation of Sozo® Digital Health Platform SoftwareImpediMed Limited announced the release of the next generation software for the SOZO Digital Health Platform. This software release, designated as Version 4.0, adds an intuitive redesign, enhanced security and privacy measures, and personalized data sets to provide clinicians with in-depth, actionable information to maximize patient health.お知らせ • May 25ImpediMed Limited Announces Official Release of SOZO Version 4.0 SoftwareImpediMed Limited announced the release of the next generation Version 4.0 software for the SOZO® Digital Health Platform. As foreshadowed in the recent quarterly Appendix 4C announcement, Version 4.0 has gone live on May 25, 2021 with a series of significant enhancements around usability, new applications and security. Within the first few hours of launch, over 70 customers have already successfully upgraded their software to Version 4.0. Improvements in the software over time have led to a continuously increasing ASP (Average Selling Price) for software licenses and a negligible customer churn rate of just 1%. Over time, ImpediMed expects similar upside resulting from the release of Version 4.0 from new features such as body composition reference ranges and a new license for Segmental Analysis, enriching clinician data and providing in-depth actionable information about patient health. Usability: In line with previous versions of software releases, there are a tremendous series of advancements in the SOZO Version 4.0 software, with a major revamp of the User Interface being the centrepiece of this release. An intuitive redesign makes the software even more intuitive and easier to use. Clinicians can now access and review data with ease. In addition, the information is customisable so clinicians can see the data in the format that is most meaningful to them. New Applications and Features: Featured in Version 4.0 for the first time are body composition reference ranges and Segmental Analysis. Body composition reference ranges give the clinician meaningful comparator data to better assess a patient's health, which is expected to lead to an increase in the adoption of the Body Composition module from within the existing customer base. The Segmental Analysis application opens new segments of the breast cancer reconstructive and lymphatic and plastic surgery markets. Based on feedback from a customer advisory board, Version 4.0 incorporates Notes and Tags, enabling clinicians to tag and make patient notes supporting clinical decision making and assist clinicians in the timely retrieval of valuable information. Version 4.0 has also allowed for the alignment of iOS and Android software, allowing for a streamlining of support and development going forward. Security: Enhanced privacy and security features such as Multi Factor Authentication (MFA) and Single SignOn (SSO) continue the track record of striving for the most stringent security measures to protect patient data. Version 3.0 brought HIPAA and Business Associate compliance and more recently HiTrust certification. Now, SOZO Version 4.0 further enhances the levels of security at the source of sign on with multifactor authentication and single sign on capability.Reported Earnings • Feb 23First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.026 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: AU$3.58m (up 26% from 1H 2020). Net loss: AU$10.4m (loss narrowed 19% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.お知らせ • Jan 21ImpediMed Limited to Report Q2, 2021 Results on Jan 28, 2021ImpediMed Limited announced that they will report Q2, 2021 results on Jan 28, 2021お知らせ • Jan 12ImpediMed Limited Announces PREVENT Trial Finishes - Final Patient Completes Follow-UpImpediMed Limited announced that the PREVENT trial is now complete and the study investigators have commenced work on a manuscript ahead of its planned submission by the end of February 2021. The Principal Investigator, Sheila H. Ridner, PhD, RN, FAAN, Professor of Nursing at Vanderbilt University School of Nursing, has communicated the following to the Company: All PREVENT trial patients have now completed their follow-up visits; No patients are still undergoing treatment; The 10 participating sites are closed, and all data is currently being compiled; The investigators expect to have the paper finalised and submitted for initial journal review by the end of February 2021. The PREVENT trial is a seminal study, the largest randomised controlled trial to be conducted on patients at-risk of lymphoedema. The study enrolled >1100 patients across 10 trial sites in the US and Australia, involving 13 hospitals. Of these, 3 of the 9 US sites are National Comprehensive Cancer Network (NCCN) Member Institutions. The trial was conducted over six and a half years and patients were followed for up to 3 years, with the primary aim to determine if subclinical detection of extracellular fluid accumulation via bioimpedance spectroscopy, and subsequent early intervention, reduces the rate of lymphoedema progression relative to the rate when using tape measurements.お知らせ • Dec 02+ 1 more updateImpedimed Limited Announces the Publication of A New Study Demonstrating That the Company's Lymphedema Prevention ProgramImpediMed Limited announced the publication of a new study demonstrating that the company's Lymphedema Prevention Program reduces the incidence of chronic breast cancer-related lymphedema in breast cancer patients and survivors. Published in Breast Cancer Research and Treatment, the meta-analysis involving 50 studies and more than 67,000 breast cancer patients confirms that routine monitoring for early detection of lymphedema using ImpediMed's L-Dex technology, combined with early intervention, cuts the relative rate of chronic breast cancer-related lymphedema by as much as 81%. Breast cancer-related lymphedema occurs when the lymphatic system is damaged by surgical, radiation or chemotherapy treatments for breast cancer. The risk of developing lymphedema ranges from 6% to 42% depending on the treatment approach. Patients suffering from lymphedema commonly experience swelling in their arms and hands that can interfere with activities of daily life and work. Treatments, including compression garments and therapy, can be costly to patients. On average, breast cancer survivors with lymphedema spend an extra $3,325 per year on medical care and productivity losses as compared to survivors without lymphedema. If left untreated, lymphedema can lead to infection and become a chronic lifelong condition. In 2019, ImpediMed introduced a comprehensive Lymphedema Prevention Program to help educate healthcare providers and patients that with proper protocols in place, subclinical lymphedema can be detected and managed before it becomes a debilitating, chronic condition. This program utilizes ImpediMed's Test, Trigger, Treat protocol for early detection and intervention of cancer-related lymphedema. Routine lymphedema testing of cancer survivors uses the company's FDA-cleared SOZO device with BIS (L-Dex) technology, which measures extracellular fluid. A significant increase in a patient's L-Dex score is a trigger to evaluate the patient and initiate intervention. ImpediMed's PREVENT Trial demonstrated that routine monitoring with L-Dex combined with at-home intervention resulted in a 95% reduction in lymphedema progression at one year. Today, L-Dex is the only non-invasive, reliable, validated tool to help clinicians identify subclinical lymphedema. The company's SOZO digital health platform can measure a patient's L-Dex score with a simple, painless 30-second scan. Monitoring L-Dex scores allows clinicians across multiple specialties to provide individualized, proactive care that can help improve patient outcomes.お知らせ • Nov 18ImpediMed Limited Secures First Commercial Heart Failure SalesImpediMed Limited announced the first order for its SOZO® Digital Health Platform to be used in the management of heart failure patients. Phoenix Healthcare Network, which operates cardio-pulmonary rehabilitation units within nursing homes and long-term care facilities, has initially purchased five SOZO units, with implementation to begin early next calendar year. The Phoenix Healthcare network of over 80 independent companies provide products and consultation services to skilled nursing facilities in the U.S. and Canada. Phoenix Healthcare provides these companies with access to innovative, state-of-the-art, "game changing" products and consultation services within their scope of practice with a focus on cardio-pulmonary rehabilitation, remote monitoring, pharmacy, and training. There are over 15,500 skilled nursing facilities in the U.S offering longer-term care to patients in need of assistance with the activities of daily life. Approximately 25% of first-time U.S. Medicare heart failure hospital patients are discharged to skilled nursing facilities, up from only 5% thirty years ago. These trends are being driven with the objective of reducing hospital readmissions and combatting chronic heart failure post-acute care costs which can comprise up to 70% of the total cost of care. The SOZO fluid analysis for heart failure is a novel tool for assessing fluid overload in heart failure patients. It utilises ImpediMed's HF-DexTM heart failure index which is a measure of extracellular fluid as a percent of total body water. HF-Dex is presented on reference ranges derived from an analysis of heart failure patients from ImpediMed's heart failure home study and research performed on healthy subjects. The heart failure home study is an observational study that tracks recently hospitalised heart failure patients with daily SOZO tests at home. The analysis yielded BIS-derived reference ranges for normal fluid volumes, elevated fluid volumes, and fluid overload, which is defined as HF-Dex greater than 51%. Data from this study, combined with individual patient case reports illustrates the benefits of SOZO in heart failure patients: Differentiating between fluid and tissue-related weight changes. Tracking response to medication changes. A marker for readmission when HF-Dex is higher than 51%.お知らせ • Nov 16ImpediMed Limited Announces NSW Health Further Expands Lymphoedema Prevention ProgramImpediMed Limited announced that New South Wales Health is further expanding patient access to its lymphoedema prevention program using the SOZO® Digital Health Platform through the purchase of 25 additional SOZO units. NSW Health is now one of the largest providers of the SOZO Digital Health Platform in Australia, with over 45 units purchased to date. In April of this year, ImpediMed announced the purchase of eight additional SOZO units, with five of these devices deployed in the Western NSW Local Health District (LHD) of NSW Health. Following successful implementation of the program, NSW Health will use the new devices to further expand patient access in both metropolitan and rural areas. NSW Health operates over 230 public hospitals in its eight local districts that cover the Sydney metropolitan region and surrounding rural areas. With nearly 45,000 new cancer cases every year, NSW is the largest public health system in Australia. As a connected health platform, SOZO allows patient's care providers to access their lymphoedema measurements at every location in the NSW Health network. The Lymphoedema Prevention Program utilises ImpediMed's Test, Trigger, TreatTM protocol for early detection and intervention of cancer-related lymphoedema. Routine lymphoedema testing of cancer survivors uses the company's SOZO device with BIS (L-Dex®) technology. A significant increase in a patient's L-Dex score is a trigger to evaluate the patient and initiate intervention. ImpediMed's PREVENT Trial, the largest multi-site, randomised controlled trial ever performed to study lymphoedema prevention, showed that this protocol resulted in a 95% reduction in lymphoedema progression at one year.お知らせ • Nov 09AstraZeneca Selects SOZO for Second Large Renal TrialImpediMed Limited announced a second contract valued at over $2.0 million for its SOZO® Digital Health Platform to be used in a clinical trial being conducted for AstraZeneca, a global pharmaceutical company. The Phase II trial will use the SOZO devices to track patient fluid volume in an upcoming pharmaceutical study focused on chronic kidney disease. The study, which is scheduled to begin in January 2021 and run for approximately 18 months, will require approximately 200 additional devices globally. The company previously announced in September 2020 that AstraZeneca will use SOZO to track patient fluid volume in a clinical trial focused on heart failure and chronic kidney disease. A combined 375 SOZO devices will now be leased across 31 countries for the two trials. Together, the trials are expected to generate in excess of $4.5 million in revenue. Under the terms of the agreement, and in alignment with the Company's SaaS business model, each device will have a monthly license fee for the duration of the study. ImpediMed will retain ownership of the devices at the conclusion of the trials.お知らせ • Oct 04HFSA Poster Supports HF-Dex in the Management of HF PatientsImpediMed Limited announced a poster presentation at the prestigious Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting, 30 September 6 October 2020. The poster combines heart failure patient data from ImpediMed's Heart Failure at Home and IMPEL studies. It demonstrates that a SOZO® with HF-DexTM assessment greater than 51% serves as a marker for heart failure hospital readmission. The findings showed a statistically significant (p<0.05) difference in median HF-Dex for patients readmitted for heart failure (52.1%) compared to patients not readmitted for heart failure (49.0%) and healthy subjects (44.8%). The patients with class II or III heart failure underwent BIS measurements in an ambulatory care setting or at home using the SOZO technology. The SOZO HF-Dex Heart Failure (HF) Index, which is extracellular fluid (ECF) as a percentage of total body water (TBW), was evaluated for differences across three groups of individuals: HF patients readmitted for acute heart failure (decompensated), HF patients not readmitted (compensated) and healthy adults aged 40+ years. Results show patients readmitted for acute heart failure had a median ECF%TBW of 52.1% supporting HF-Dex greater than 51% is a marker for readmission. The compensated group had a median ECF%TBW of 49.0%, and the healthy population's median was 44.8%. The SOZO HF-Dex heart failure index is a novel tool for assessing fluid overload in heart failure. Data from this poster, combined with individual patient case reports illustrates additional benefits of SOZO in heart failure patients: Differentiating between fluid and tissue-related weight changes, Tracking response to medication changes, A marker for readmission when HF-Dex is higher than 51%.お知らせ • Oct 03Impedimed Limited Announces Collaboration with the Live Today Foundation to Increase Awareness and Access to Care for Cancer Patients At Risk or Suffering from LymphedemaImpediMed Limited announced a collaboration with the LIVE Today Foundation. Introduced at the start of Breast Cancer Awareness Month, the partnership involves activities that reflect a joint mission of improving awareness as well as access to care for cancer patients in the U.S. who are at risk of developing lymphedema or are struggling with it. ImpediMed will provide support to the foundation for the purchase and distribution of lymphedema compression garments to underserved patients as well as help to develop and implement educational programs for physicians and patients. Currently, one in three cancer survivors will develop secondary lymphedema related to their cancer treatment, costing the U.S. healthcare system approximately $7 billion every year. In 2019, ImpediMed introduced a comprehensive Lymphedema Prevention Program to help educate healthcare providers and patients that with proper protocols in place, lymphedema can be detected and managed before it becomes a debilitating, chronic condition. This program utilizes ImpediMed's Test, Trigger, Treat™ protocol for early detection and intervention of cancer-related lymphedema. Routine lymphedema testing of cancer survivors uses the company's FDA-cleared SOZO® device with BIS (L-Dex®) technology, which measures extracellular fluid. A significant increase in a patient's L-Dex score is a trigger to evaluate the patient and initiate intervention. ImpediMed's PREVENT Trial demonstrated that routine monitoring with L-Dex combined with at-home intervention resulted in a 95% reduction in lymphedema progression at one year. Today, L-Dex is the only non-invasive, reliable, validated tool to help clinicians identify subclinical lymphedema. The company's SOZO digital health platform can measure a patient's L-Dex score with a simple, painless 30-second scan. Monitoring L-Dex scores allows clinicians across multiple specialties to provide individualized, proactive care that can help improve patient outcomes.お知らせ • Sep 30Impedimed Limited Announces Contract Valued at over AUD 2 Million for its SOZO Digital Health Platform to Be Used in Clinical Trial Being Conducted for AstraZenecaImpediMed Limited announced a contract valued at over AUD 2 million for its SOZO® Digital Health Platform to be used in a clinical trial being conducted for AstraZeneca. The Phase II trial will use the SOZO devices to track patient fluid volume in an upcoming pharmaceutical study focused on heart failure and chronic kidney disease. The study, which will begin in the second fiscal quarter and run for approximately 18 months, will require approximately 175 devices globally. AstraZeneca has used ImpediMed’s BIS technology for a number of years to measure subjects’ fluid volumes in their clinical studies. With SOZO, they will be able to achieve the fluid measurement accuracy of gold standard dilution methods in a test that takes 30 seconds instead of up to 24 hours. Add in the fact that it offers real-time data review globally, and it’s clear why the SOZO Digital Health Platform was chosen for this new research. The AstraZeneca study using SOZO will evaluate the efficacy, safety, and tolerability of a combination of two AstraZeneca drugs in heart failure patients with chronic kidney disease. This Phase II trial is scheduled to begin in November 2020. The trial is being run by a contract research organization on behalf of AstraZeneca. Under the terms of the agreement, and in alignment with the Company’s SaaS business model, each device will have a monthly license fee for the duration of the study. ImpediMed will retain ownership of the devices at the conclusion of the trials. SOZO is FDA-cleared for heart failure and CE-Marked for heart failure and renal failure. The trial will provide a significant number of cardiologists, both in the US and globally, firsthand experience with SOZO and coincides with ImpediMed’s launch into the cardiology market. Cardiovascular disease is the leading cause of death among those with kidney disease. Among hospitalizations for primary heart failure, one of the most common comorbid diagnoses is chronic kidney disease (47%).お知らせ • Sep 21ImpediMed Limited(ASX:IPD) dropped from S&P/ASX Emerging Companies IndexImpediMed Limited(ASX:IPD) dropped from S&P/ASX Emerging Companies Indexお知らせ • Sep 01ImpediMed Limited Auditor Raises 'Going Concern' DoubtImpediMed Limited filed its Annual on Aug 25, 2020 for the period ending Jun 30, 2020. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.お知らせ • Jul 21ImpediMed Limited to Report Q4, 2020 Results on Jul 28, 2020ImpediMed Limited announced that they will report Q4, 2020 results at 9:21 PM, GMT Standard Time on Jul 28, 2020お知らせ • Jul 07ImpediMed Limited announced that it has received AUD 0.227339 million in fundingImpediMed Limited (ASX:IPD) announced a private placement of 3,444,527 ordinary shares at a price of AUD 0.066 per share for the gross proceeds of AUD 227338.782 on July 1, 2020. The transaction will include participation from executives and nonexecutive directors of the company. The transaction has been approved by the shareholders of the company at annual general meeting.業績と収益の成長予測CHIA:IPD - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/202828-7-9-436/30/202720-14-16-1336/30/202615-22-22-18212/31/202514-24-16-15N/A9/30/202513-24-16-15N/A6/30/202513-23-16-15N/A3/31/202512-22-18-17N/A12/31/202412-21-21-19N/A9/30/202411-21-21-18N/A6/30/202410-20-21-18N/A3/31/202410-20-19-15N/A12/31/202310-19-18-13N/A9/30/202311-20-21-15N/A6/30/202311-21-24-18N/A3/31/202311-21-25-20N/A12/31/202211-22-27-22N/A9/30/202211-21-24-19N/A6/30/202211-20-21-16N/A3/31/202210-20-19-14N/A12/31/202110-19-17-13N/A9/30/20219-20-16-13N/A6/30/20218-21-16-13N/A3/31/20217-20-17-15N/A12/31/20206-19-18-16N/A9/30/20206-20-20-18N/A6/30/20206-21-21-19N/A12/31/20195-25-22-20N/A9/30/20195-24N/A-20N/A6/30/20194-24N/A-20N/A12/31/20184-25N/A-21N/A9/30/20183-26N/A-22N/A6/30/20183-27N/A-23N/A3/31/20184-28N/AN/AN/A12/31/20174-28N/A-26N/A9/30/20175-28N/A-26N/A6/30/20176-28N/A-26N/A3/31/20176-28N/A-25N/A12/31/20166-29N/A-25N/A9/30/20166-27N/A-24N/A6/30/20166-26N/A-22N/A3/31/20166-23N/A-19N/A12/31/20155-20N/A-16N/A9/30/20155-17N/A-13N/A6/30/20155-15N/A-11N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: IPD今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: IPD今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: IPD今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: IPDの収益 ( 29.4% ) Australian市場 ( 6.2% ) よりも速いペースで成長すると予測されています。高い収益成長: IPDの収益 ( 29.4% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: IPDの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/05 17:22終値2026/06/05 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ImpediMed Limited 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関James WilliamsonBell PotterMartyn JacobsBell PotterShane StoreyCanaccord Genuity2 その他のアナリストを表示
Breakeven Date Change • Aug 18No longer forecast to breakevenThe 3 analysts covering ImpediMed no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$5.04m in 2027. New consensus forecast suggests the company will make a loss of AU$2.53m in 2027.
Breakeven Date Change • Aug 29Forecast to breakeven in 2027The 2 analysts covering ImpediMed expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$23.7m in 2027. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Breakeven Date Change • Jul 30Forecast to breakeven in 2026The 4 analysts covering ImpediMed expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$1.95m in 2026. Average annual earnings growth of 54% is required to achieve expected profit on schedule.
Breakeven Date Change • Feb 03No longer forecast to breakevenThe 3 analysts covering ImpediMed no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$3.15m in 2026. New consensus forecast suggests the company will make a loss of AU$2.18m in 2026.
Breakeven Date Change • May 30No longer forecast to breakevenThe 4 analysts covering ImpediMed no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$891.8k in 2025. New consensus forecast suggests the company will make a loss of AU$377.6k in 2025.
Breakeven Date Change • Apr 27No longer forecast to breakevenThe 3 analysts covering ImpediMed no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$2.63m in 2024. New consensus forecast suggests the company will make a loss of AU$6.03m in 2024.
Board Change • May 20High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Janelle Delaney is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • May 06+ 1 more updateImpediMed Limited has completed a Follow-on Equity Offering in the amount of AUD 13.2 million.ImpediMed Limited has completed a Follow-on Equity Offering in the amount of AUD 13.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 300,000,000 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,020,000,000 Price\Range: AUD 0.01 Transaction Features: Subsequent Direct Listing
お知らせ • Apr 08+ 1 more updateImpediMed Limited Announces Chief Executive Officer ChangesImpediMed Limited announced the appointment of Erik Anderson as Chief Executive Officer. Anderson, who joined the company's Board of Directors in February 2026, succeeds Dr. Parmjot Bains. His appointment is effective April 7, 2026. Anderson's appointment comes as ImpediMed's business gains momentum with its Breast Cancer Related Lymphedema (BCRL) business. The Board determined that the next phase of growth requires a step change in commercial execution, particularly in the United States. Anderson's appointment reflects a focus on accelerating revenue growth, expanding health system adoption, managing costs, and advancing the company toward cash flow break-even and long-term value creation. Anderson brings to ImpediMed extensive commercial leadership experience in the US medical technology sector. Most recently, he served as President of the Breast and Skeletal Health Division at Hologic Inc. . During his tenure at Hologic, he led a large, multi-franchise commercial organization and grew one of the company's largest business units—a $1.6+ billion global franchise. He also brings deep expertise in healthcare delivery, including hospital sales, clinical adoption, and reimbursement, along with strong relationships across health systems and key stakeholders aligned with ImpediMed's growth priorities in BCRL, body composition, and heart health. With this experience, Anderson is well-positioned to lead ImpediMed's next phase of growth, expanding sales and distribution across U.S. health systems. Bains will continue in an advisory role through June 30, 2026, to support a smooth leadership transition.
お知らせ • Jan 27ImpediMed Limited to Report Q2, 2026 Results on Jan 29, 2026ImpediMed Limited announced that they will report Q2, 2026 results on Jan 29, 2026
Board Change • Dec 24High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Janelle Delaney is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Oct 24ImpediMed Limited to Report Q1, 2026 Results on Oct 30, 2025ImpediMed Limited announced that they will report Q1, 2026 results on Oct 30, 2025
お知らせ • Sep 19ImpediMed Limited, Annual General Meeting, Nov 18, 2025ImpediMed Limited, Annual General Meeting, Nov 18, 2025.
Reported Earnings • Aug 29Full year 2025 earnings released: AU$0.012 loss per share (vs AU$0.01 loss in FY 2024)Full year 2025 results: AU$0.012 loss per share (further deteriorated from AU$0.01 loss in FY 2024). Revenue: AU$12.7m (up 23% from FY 2024). Net loss: AU$23.2m (loss widened 17% from FY 2024). Revenue is forecast to grow 48% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Aug 18No longer forecast to breakevenThe 3 analysts covering ImpediMed no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$5.04m in 2027. New consensus forecast suggests the company will make a loss of AU$2.53m in 2027.
お知らせ • Jul 16ImpediMed Limited to Report Q4, 2025 Results on Jul 31, 2025ImpediMed Limited announced that they will report Q4, 2025 results on Jul 31, 2025
お知らせ • Apr 17ImpediMed Limited to Report Q3, 2025 Results on Apr 30, 2025ImpediMed Limited announced that they will report Q3, 2025 results on Apr 30, 2025
お知らせ • Jan 28ImpediMed Limited to Report Q2, 2025 Results on Jan 31, 2025ImpediMed Limited announced that they will report Q2, 2025 results on Jan 31, 2025
Board Change • Dec 24Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. 2 independent directors (4 non-independent directors). Independent Non-Executive Director Janelle Delaney is the most experienced director on the board, commencing their role in 2023. Independent Non-Executive Chair Christine Emmanuel-Donnelly was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Oct 15ImpediMed Limited to Report Q1, 2025 Results on Oct 22, 2024ImpediMed Limited announced that they will report Q1, 2025 results on Oct 22, 2024
お知らせ • Sep 27ImpediMed Limited, Annual General Meeting, Nov 19, 2024ImpediMed Limited, Annual General Meeting, Nov 19, 2024.
Recent Insider Transactions • Sep 03Board Member recently bought AU$73k worth of stockOn the 30th of August, Andrew Grant bought around 1m shares on-market at roughly AU$0.073 per share. This transaction increased Andrew's direct individual holding by 3x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$544k more in shares than they have sold in the last 12 months.
Reported Earnings • Aug 30Full year 2024 earnings released: EPS: AU$0 (vs AU$0.011 loss in FY 2023)Full year 2024 results: EPS: AU$0 (improved from AU$0.011 loss in FY 2023). Revenue: AU$10.3m (down 9.0% from FY 2023). Net loss: AU$19.8m (loss narrowed 3.6% from FY 2023). Revenue is forecast to grow 50% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Aug 29Forecast to breakeven in 2027The 2 analysts covering ImpediMed expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$23.7m in 2027. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
お知らせ • Aug 23ImpediMed Limited to Report Fiscal Year 2024 Results on Aug 29, 2024ImpediMed Limited announced that they will report fiscal year 2024 results Pre-Market on Aug 29, 2024
Breakeven Date Change • Jul 30Forecast to breakeven in 2026The 4 analysts covering ImpediMed expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$1.95m in 2026. Average annual earnings growth of 54% is required to achieve expected profit on schedule.
お知らせ • Jul 22+ 3 more updatesImpediMed Limited Appoints Parmjot Bains as CEO on an ongoing basisAs announced in November 2023, Dr. Parmjot Bains, CEO and Managing Director commenced in their roles in an interim capacity. The Board of ImpediMed Limited confirmed the appointment of Dr. Bains as Chief Executive Officer on an ongoing basis. In the 6-month period in their interim roles, Dr. Bains has implemented a number of significant changes across the business to ensure the Company is in the best position to achieve growth and profitability and ensure all patients at risk of cancer related lymphedema can access ImpediMed's unique technology.
お知らせ • Jun 08ImpediMed Limited Appoints Fiona Bones as A Non-Executive DirectorThe Board of ImpediMed Limited announced the appointment of Ms Fiona Bones as a non-Executive Director of the Company, effective 07 June 2024. Ms Bones is currently VP of Finance, International Controller at Google and has worked at Google for over 20 years. Ms Bones is a Fellow of the Association of Chartered Certified Accountants, UK and Ireland and brings global experience in finance, corporate governance, and systems transformation.
New Risk • Jun 04New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$149.7m (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$8.1m net loss in 2 years). Market cap is less than US$100m (AU$149.7m market cap, or US$99.4m).
Recent Insider Transactions • May 15Independent Non-Executive Director recently bought AU$50k worth of stockOn the 8th of May, Janelle Delaney bought around 634k shares on-market at roughly AU$0.079 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth AU$100k. Insiders have collectively bought AU$883k more in shares than they have sold in the last 12 months.
お知らせ • Apr 20ImpediMed Limited to Report Q3, 2024 Results on Apr 30, 2024ImpediMed Limited announced that they will report Q3, 2024 results on Apr 30, 2024
お知らせ • Apr 11ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual MeetingImpediMed announced that it will present new results from a breast cancer-related lymphedema study during a poster session at the American Society of Breast Surgeons (ASBrS) Annual Meeting in Orlando, FL on April 12, 2024. The study, titled "Timing of Breast Cancer-related Lymphedema Development Over Three Years: Observations from a Large, Prospective Randomized Screening Trial," revealed that patients at risk of developing breast cancer related lymphedema (BRCL) should continue to be monitored for three years following the completion of cancer treatment, as patients could trigger at any time over this period. The results are part of PREVENT, the largest randomized control trial to assess lymphedema prevention, in 1200 women, which monitored progression to BCRL following intervention for BCRL assessed by both bioimpedance spectroscopy (BIS) and a tape measure, demonstrating lower progression to chronic lymphedema with early detection using BIS and intervention versus using tape measure. Lymphedema, a common consequence of cancer treatment, poses significant challenges in healthcare. According to the American Cancer Society 58% of cancer patients diagnosed with breast cancer, melanoma, or pelvic area cancers are at risk for developing limb lymphedema, and over 80% of breast cancer patients are at risk. ImpediMed has the only FDA-cleared BIS technology for the clinical assessment of lymphedema. The Company's SOZO® Digital Health Platform is broadly accepted and recognized for effective and accurate screening of lymphedema, with US payors now providing coverage for over 140 million covered lives. The PREVENT trial is a pivotal study and the largest randomized controlled trial to assess lymphedema prevention. The study enrolled 1,200 patients across 10 trial sites in the US and Australia, involving 13 hospitals, including Vanderbilt University, Mayo Clinic and MD Anderson. The trial was conducted over six and a half years and patients were followed for up to three years, with the primary aim to determine if early intervention in patients with subclinical detection of extracellular fluid accumulation via bioimpedance spectroscopy results in a lower rate of lymphedema progression versus the rate when tape measure is used for subclinical detection. The manuscript is published in Lymphatic Research and Biology. The results of the trial demonstrated that patients with early detection with L-Dex™ technology and at-home intervention with compression garments resulted in a 7.9% rate of chronic lymphedema compared to a 19.2% rate of chronic lymphedema using tape measure. The difference is statistically significant (p=0.016) as well as being clinically significant for patients and clinicians. This represents an absolute reduction of 11.3% and relative reduction of 59% in lymphedema progression at three years.
Recent Insider Transactions • Mar 28Independent Non-Executive Director recently bought AU$100k worth of stockOn the 25th of March, Janelle Delaney bought around 1m shares on-market at roughly AU$0.087 per share. This transaction amounted to 54% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$905k more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Mar 02Independent Non-Executive Director recently bought AU$90k worth of stockOn the 29th of February, Andrew Grant bought around 230k shares on-market at roughly AU$0.39 per share. This transaction increased Andrew's direct individual holding by 3x at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth AU$135k. Insiders have collectively bought AU$898k more in shares than they have sold in the last 12 months.
Breakeven Date Change • Feb 03No longer forecast to breakevenThe 3 analysts covering ImpediMed no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$3.15m in 2026. New consensus forecast suggests the company will make a loss of AU$2.18m in 2026.
Board Change • Feb 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Janelle Delaney is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Jan 23ImpediMed Limited to Report First Half, 2024 Results on Feb 27, 2024ImpediMed Limited announced that they will report first half, 2024 results on Feb 27, 2024
Recent Insider Transactions • Dec 19Independent Non-Executive Director recently bought AU$135k worth of stockOn the 14th of December, Janelle Delaney bought around 942k shares on-market at roughly AU$0.14 per share. This transaction increased Janelle's direct individual holding by 14x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$814k more in shares than they have sold in the last 12 months.
お知らせ • Nov 20+ 2 more updatesImpediMed Limited Announces CFO ChangesImpediMed Limited announced leadership and Board changes to drive growth and manage costs. When elected, the Board announced a review of ImpediMed's strategy to ensure it was maximising the potential opportunities to transition to a high growth and profitable business. To date, the Board has considered the Company's operational readiness, approach to execution and cost structure. The review identified a very capable core management team, a distinctive product portfolio and an undeniable opportunity. However, more is needed to deliver robust execution and control costs. Given these challenges and the strong endorsement for change from ImpediMed shareholders at the recent General Meeting, the Board has determined that action now is appropriate. Tim Cruickshank has stepped down as CFO and the Board is discussing transition arrangements with him. Chair McGregor Grant assumes the responsibilities of CFO effective immediately, in an interim capacity and will be an Executive Chairman. The Chair, McGregor Grant will work closely with Dr. Bains as CFO, with a clear focus on managing costs. managing costs. For the last 12 years Mr. Grant was CFO and company Secretary of Nanosonics Limited. As well as leading financial strategy, Mr. Grant played a key role in developing and implementing corporate strategy. He was also responsible for operational functions including IT, legal and facilities management. During Mr. Grant's tenure at Nanosonics revenue grew from $2 million to $166 million. Together, Dr. Bains and Mr. Grant have extensive strategic, sales & marketing, financial and operational experience in high growth MedTech/healthcare businesses and will ensure stability and continuity of the business' operations. The Board recognises the significant talent within the senior management team, and Dr. Bains and Mr. Grant look forward to working closely with them to ensure the entire ImpediMed team remains focused on execution. Dr. Bains and Mr. Grant will also work closely with the management team to more deeply examine the Company's strategic and operational plans and its cost base to maximise the commercial opportunity and deliver value to its shareholders. Dr. Bains and Mr. Grant have been appointed to their roles in an interim capacity, which is expected to be in place for a period of up to six months while they assess the requirements of the business.
お知らせ • Oct 24ImpediMed Limited to Report Q1, 2024 Results on Oct 31, 2023ImpediMed Limited announced that they will report Q1, 2024 results on Oct 31, 2023
お知らせ • Oct 12ImpediMed Limited, Annual General Meeting, Nov 30, 2023ImpediMed Limited, Annual General Meeting, Nov 30, 2023, at 10:01 E. Australia Standard Time.
Board Change • Oct 05High number of new directorsThere are 8 new directors who have joined the board in the last 3 years. Director McGregor Grant was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 27ImpediMed Limited Announce the Appointment of Steven Chen as Chief Medical OfficerImpediMed Limited announced the appointment of Steven Chen, MD, MBA as Chief Medical Officer effective 26 September 2023. Dr. Chen is a board-certified surgical oncologist who brings strong business acumen and extensive leadership experience in cancer care and the healthcare industry. Dr. Chen's previous leadership and experience: Chief Medical Officer of Avelas Biosciences, a clinical stage drug-device company dedicated to improving cancer care. Chief of Breast Surgery, University of California Davis Medical Center. Associate Program Director of the surgical oncology training program at City of Hope National Medical Center, Duarte, California. Past President, American Society of Breast Surgeons (ASBrS). Clinical training at the John Wayne Cancer Institute, the University of Michigan and the Center for Health Care Economics. Over 70 publications and 5,000 citations. The University of California Davis, the City of Hope, and the University of Michigan are members of the National Comprehensive Cancer Network (NCCN®). Most recently, Dr. Chen served as the Chief Medical Officer of Avelas, a clinical stage drug-device company dedicated to improving cancer care. There, he successfully oversaw their lead asset through Investigational New Drug (IND) application and first in human studies through pivotal trials and established the company's clinical strategy to support commercialisation and reimbursement. Previously, Dr. Chen served as the Chief of Breast Surgery at UC Davis Medical Center, followed by a position as an Associate Professor of Surgery and as the Associate Program Director of the surgical oncology training program at City of Hope National Medical Center in Duarte, California. He is a past President of the American Society of Breast Surgeons and serves or served on committees for a number of professional societies including the American Medical Association, the Society of Surgical Oncology, and the American College of Surgeons. Dr. Chen is a practicing surgeon in San Diego, California and the Director of Surgical Oncology at OasisMD. Dr. Chen received his medical degree and completed general surgery and critical care residencies at the University of Michigan, followed by a surgical oncology fellowship at the John Wayne Cancer Institute. Dr. Chen also obtained his master's in business administration at the University of Michigan's Ross School of Business.
Reported Earnings • Aug 31Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.012 loss in FY 2022)Full year 2023 results: AU$0.01 loss per share. Revenue: AU$11.3m (up 7.4% from FY 2022). Net loss: AU$20.5m (loss widened 3.3% from FY 2022). Revenue is forecast to grow 55% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia.
お知らせ • Jul 17ImpediMed Limited to Report Q4, 2023 Results on Jul 24, 2023ImpediMed Limited announced that they will report Q4, 2023 results on Jul 24, 2023
お知らせ • Jul 06ImpediMed Limited Appoints Daniel Sharp as DirectorImpediMed Limited appointed Mr. Daniel Sharp as director, date of appointment is July 1, 2023.
Recent Insider Transactions • Jun 28Executive Director recently bought AU$144k worth of stockOn the 20th of June, David Anderson bought around 920k shares on-market at roughly AU$0.16 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth AU$158k. Insiders have collectively bought AU$1.0m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Jun 14Independent Non-Executive Chairman recently bought AU$82k worth of stockOn the 6th of June, Donald Williams bought around 500k shares on-market at roughly AU$0.16 per share. This transaction amounted to 7.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Donald has been a buyer over the last 12 months, purchasing a net total of AU$273k worth in shares.
Breakeven Date Change • May 30No longer forecast to breakevenThe 4 analysts covering ImpediMed no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$891.8k in 2025. New consensus forecast suggests the company will make a loss of AU$377.6k in 2025.
Recent Insider Transactions • Apr 22MD, CEO & Director recently bought AU$52k worth of stockOn the 20th of April, Richard Valencia bought around 410k shares on-market at roughly AU$0.13 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth AU$64k. Richard has been a buyer over the last 12 months, purchasing a net total of AU$170k worth in shares.
Recent Insider Transactions • Mar 31MD, CEO & Director recently bought AU$54k worth of stockOn the 27th of March, Richard Valencia bought around 400k shares on-market at roughly AU$0.13 per share. This transaction amounted to 40% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth AU$64k. Richard has been a buyer over the last 12 months, purchasing a net total of AU$118k worth in shares.
Recent Insider Transactions • Mar 08MD, CEO & Director recently bought AU$64k worth of stockOn the 6th of March, Richard Valencia bought around 1m shares on-market at roughly AU$0.064 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Richard's only on-market trade for the last 12 months.
Reported Earnings • Feb 25First half 2023 earnings released: AU$0.01 loss per share (vs AU$0.006 loss in 1H 2022)First half 2023 results: AU$0.01 loss per share (further deteriorated from AU$0.006 loss in 1H 2022). Revenue: AU$5.66m (up 8.8% from 1H 2022). Net loss: AU$10.8m (loss widened 21% from 1H 2022). Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
お知らせ • Jan 24ImpediMed Limited to Report Q2, 2023 Results on Jan 30, 2023ImpediMed Limited announced that they will report Q2, 2023 results on Jan 30, 2023
Board Change • Nov 17Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Bob Graham was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Nov 01Executive Director & Interim CEO recently bought AU$164k worth of stockOn the 28th of October, David Anderson bought around 2m shares on-market at roughly AU$0.094 per share. This transaction amounted to 89% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was David's only on-market trade for the last 12 months.
Board Change • Oct 29Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Bob Graham was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 30Full year 2022 earnings released: AU$0.01 loss per share (vs AU$0.017 loss in FY 2021)Full year 2022 results: AU$0.01 loss per share (up from AU$0.017 loss in FY 2021). Revenue: AU$10.6m (up 26% from FY 2021). Net loss: AU$19.9m (loss narrowed 4.0% from FY 2021). Over the next year, revenue is forecast to grow 84%, compared to a 14% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
Board Change • Jul 28Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Bob Graham was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Breakeven Date Change • Apr 27No longer forecast to breakevenThe 3 analysts covering ImpediMed no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$2.63m in 2024. New consensus forecast suggests the company will make a loss of AU$6.03m in 2024.
お知らせ • Mar 07New Bone Data Showing Strong Correlation Between ImpediMed's SOZO and DXA in Cancer Patients Presented At 39Th Annual Miami Breast Cancer ConferenceImpediMed Limited announced a poster showing strong correlation between ImpediMed's SOZO® Digital Health Platform and dual x-ray absorptiometry (DXA) for assessing bone mineral content in cancer patients was presented at the 39th Annual Miami Breast Cancer Conference on 3-6 March 2022 in Miami Beach, Florida, USA. The Miami Breast Cancer Conference draws leaders in breast cancer care for in-depth discussions about current topics and technologies. The poster is available to registered attendees in-person and online. Abstracts will be published online following the conference in the journal Oncology. The poster titled "The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device" demonstrated strong correlation between skeletal muscle mass (SMM) collected using SOZO and bone mineral content (BMC) collected using DXA in three groups: There are 16.9 million cancer survivors in the US and approximately 32 million worldwide. The majority of survivors are women with early-stage breast cancers and men with nonmetastatic prostate cancers. These patients frequently receive hormonal manipulation therapies that can significantly impact their bone mineral content. These patients have a higher risk of bone fractures potentially leading to hospitalisation and death. Multiple studies have shown a strong correlation between SMM and bone suggesting that a SOZO reading can provide a simple, quick, and reproducible estimate of BMC. Expanding the use of SOZO to help care for cancer patients is central to ImpediMed's growth strategy in oncology. Lymphoedema provides a strong entry point for the adoption of SOZO into oncology practices and remains the Company's key focus in the short term. Over the medium term, developing new broader oncology indications creates the opportunity to expand through demand for additional SOZO devices and adding new licenses to existing devices. Bone is one of a number of potential indications on ImpediMed's oncology product roadmap. Several large corporate accounts, as well as some prestigious institutions, have expressed an interest in the co-development of these potential indications with the goal of benefiting their cancer patients and improving health economics. The Company has initiated some small-scale clinical investigations and is currently assessing the opportunities. More information will be provided as they progress.
Breakeven Date Change • Mar 05No longer forecast to breakevenThe 4 analysts covering ImpediMed no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$2.63m in 2024. New consensus forecast suggests the company will make a loss of AU$4.12m in 2024.
Reported Earnings • Mar 01First half 2022 earnings: EPS in line with expectations, revenues disappointFirst half 2022 results: AU$0.006 loss per share (up from AU$0.01 loss in 1H 2021). Revenue: AU$5.20m (up 45% from 1H 2021). Net loss: AU$8.92m (loss narrowed 14% from 1H 2021). Revenue missed analyst estimates by 2.2%. Over the next year, revenue is forecast to grow 90%, compared to a 19% growth forecast for the industry in Australia. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Buying Opportunity • Feb 15Now 22% undervaluedOver the last 90 days, the stock is up 2.9%. The fair value is estimated to be AU$0.23, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% per annum over the last 3 years. Earnings per share has grown by 44% per annum over the last 3 years.
Breakeven Date Change • Sep 23Forecast to breakeven in 2024The 3 analysts covering ImpediMed expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$100.0k in 2024. Average annual earnings growth of 61% is required to achieve expected profit on schedule.
お知らせ • Aug 31FDA Grants Breakthrough Device Designation for ImpediMed's SOZO Digital Health Platform for Renal FailureImpediMed Limited announced that the SOZO Digital Health Platform was designated a Breakthrough Device by the Food and Drug Administration (FDA) for a proposed indication in renal failure. Using bioimpedance spectroscopy, the SOZO® Digital Health Platform aims to provide clinicians with a more precise measure of fluid volume to be removed from a renal failure patient during dialysis. The current standard-of-care method to measure the accumulation of fluid in kidney failure patients utilizes weight scales. These scales cannot account for changes in body composition, with muscle loss being a common side effect of end-stage renal disease patients. The potential for SOZO® to address this deficiency was paramount in the FDA awarding its Breakthrough Designation to the SOZO® Digital Health Platform. The Breakthrough Device Designation is granted when a device meets several criteria, including providing for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions.
Reported Earnings • Aug 26Full year 2021 earnings released: AU$0.02 loss per share (vs AU$0.036 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: AU$8.41m (up 47% from FY 2020). Net loss: AU$20.7m (loss narrowed 3.1% from FY 2020). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
お知らせ • Jun 08Impedimed Announces Next Generation of Sozo® Digital Health Platform SoftwareImpediMed Limited announced the release of the next generation software for the SOZO Digital Health Platform. This software release, designated as Version 4.0, adds an intuitive redesign, enhanced security and privacy measures, and personalized data sets to provide clinicians with in-depth, actionable information to maximize patient health.
お知らせ • May 25ImpediMed Limited Announces Official Release of SOZO Version 4.0 SoftwareImpediMed Limited announced the release of the next generation Version 4.0 software for the SOZO® Digital Health Platform. As foreshadowed in the recent quarterly Appendix 4C announcement, Version 4.0 has gone live on May 25, 2021 with a series of significant enhancements around usability, new applications and security. Within the first few hours of launch, over 70 customers have already successfully upgraded their software to Version 4.0. Improvements in the software over time have led to a continuously increasing ASP (Average Selling Price) for software licenses and a negligible customer churn rate of just 1%. Over time, ImpediMed expects similar upside resulting from the release of Version 4.0 from new features such as body composition reference ranges and a new license for Segmental Analysis, enriching clinician data and providing in-depth actionable information about patient health. Usability: In line with previous versions of software releases, there are a tremendous series of advancements in the SOZO Version 4.0 software, with a major revamp of the User Interface being the centrepiece of this release. An intuitive redesign makes the software even more intuitive and easier to use. Clinicians can now access and review data with ease. In addition, the information is customisable so clinicians can see the data in the format that is most meaningful to them. New Applications and Features: Featured in Version 4.0 for the first time are body composition reference ranges and Segmental Analysis. Body composition reference ranges give the clinician meaningful comparator data to better assess a patient's health, which is expected to lead to an increase in the adoption of the Body Composition module from within the existing customer base. The Segmental Analysis application opens new segments of the breast cancer reconstructive and lymphatic and plastic surgery markets. Based on feedback from a customer advisory board, Version 4.0 incorporates Notes and Tags, enabling clinicians to tag and make patient notes supporting clinical decision making and assist clinicians in the timely retrieval of valuable information. Version 4.0 has also allowed for the alignment of iOS and Android software, allowing for a streamlining of support and development going forward. Security: Enhanced privacy and security features such as Multi Factor Authentication (MFA) and Single SignOn (SSO) continue the track record of striving for the most stringent security measures to protect patient data. Version 3.0 brought HIPAA and Business Associate compliance and more recently HiTrust certification. Now, SOZO Version 4.0 further enhances the levels of security at the source of sign on with multifactor authentication and single sign on capability.
Reported Earnings • Feb 23First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.026 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: AU$3.58m (up 26% from 1H 2020). Net loss: AU$10.4m (loss narrowed 19% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.
お知らせ • Jan 21ImpediMed Limited to Report Q2, 2021 Results on Jan 28, 2021ImpediMed Limited announced that they will report Q2, 2021 results on Jan 28, 2021
お知らせ • Jan 12ImpediMed Limited Announces PREVENT Trial Finishes - Final Patient Completes Follow-UpImpediMed Limited announced that the PREVENT trial is now complete and the study investigators have commenced work on a manuscript ahead of its planned submission by the end of February 2021. The Principal Investigator, Sheila H. Ridner, PhD, RN, FAAN, Professor of Nursing at Vanderbilt University School of Nursing, has communicated the following to the Company: All PREVENT trial patients have now completed their follow-up visits; No patients are still undergoing treatment; The 10 participating sites are closed, and all data is currently being compiled; The investigators expect to have the paper finalised and submitted for initial journal review by the end of February 2021. The PREVENT trial is a seminal study, the largest randomised controlled trial to be conducted on patients at-risk of lymphoedema. The study enrolled >1100 patients across 10 trial sites in the US and Australia, involving 13 hospitals. Of these, 3 of the 9 US sites are National Comprehensive Cancer Network (NCCN) Member Institutions. The trial was conducted over six and a half years and patients were followed for up to 3 years, with the primary aim to determine if subclinical detection of extracellular fluid accumulation via bioimpedance spectroscopy, and subsequent early intervention, reduces the rate of lymphoedema progression relative to the rate when using tape measurements.
お知らせ • Dec 02+ 1 more updateImpedimed Limited Announces the Publication of A New Study Demonstrating That the Company's Lymphedema Prevention ProgramImpediMed Limited announced the publication of a new study demonstrating that the company's Lymphedema Prevention Program reduces the incidence of chronic breast cancer-related lymphedema in breast cancer patients and survivors. Published in Breast Cancer Research and Treatment, the meta-analysis involving 50 studies and more than 67,000 breast cancer patients confirms that routine monitoring for early detection of lymphedema using ImpediMed's L-Dex technology, combined with early intervention, cuts the relative rate of chronic breast cancer-related lymphedema by as much as 81%. Breast cancer-related lymphedema occurs when the lymphatic system is damaged by surgical, radiation or chemotherapy treatments for breast cancer. The risk of developing lymphedema ranges from 6% to 42% depending on the treatment approach. Patients suffering from lymphedema commonly experience swelling in their arms and hands that can interfere with activities of daily life and work. Treatments, including compression garments and therapy, can be costly to patients. On average, breast cancer survivors with lymphedema spend an extra $3,325 per year on medical care and productivity losses as compared to survivors without lymphedema. If left untreated, lymphedema can lead to infection and become a chronic lifelong condition. In 2019, ImpediMed introduced a comprehensive Lymphedema Prevention Program to help educate healthcare providers and patients that with proper protocols in place, subclinical lymphedema can be detected and managed before it becomes a debilitating, chronic condition. This program utilizes ImpediMed's Test, Trigger, Treat protocol for early detection and intervention of cancer-related lymphedema. Routine lymphedema testing of cancer survivors uses the company's FDA-cleared SOZO device with BIS (L-Dex) technology, which measures extracellular fluid. A significant increase in a patient's L-Dex score is a trigger to evaluate the patient and initiate intervention. ImpediMed's PREVENT Trial demonstrated that routine monitoring with L-Dex combined with at-home intervention resulted in a 95% reduction in lymphedema progression at one year. Today, L-Dex is the only non-invasive, reliable, validated tool to help clinicians identify subclinical lymphedema. The company's SOZO digital health platform can measure a patient's L-Dex score with a simple, painless 30-second scan. Monitoring L-Dex scores allows clinicians across multiple specialties to provide individualized, proactive care that can help improve patient outcomes.
お知らせ • Nov 18ImpediMed Limited Secures First Commercial Heart Failure SalesImpediMed Limited announced the first order for its SOZO® Digital Health Platform to be used in the management of heart failure patients. Phoenix Healthcare Network, which operates cardio-pulmonary rehabilitation units within nursing homes and long-term care facilities, has initially purchased five SOZO units, with implementation to begin early next calendar year. The Phoenix Healthcare network of over 80 independent companies provide products and consultation services to skilled nursing facilities in the U.S. and Canada. Phoenix Healthcare provides these companies with access to innovative, state-of-the-art, "game changing" products and consultation services within their scope of practice with a focus on cardio-pulmonary rehabilitation, remote monitoring, pharmacy, and training. There are over 15,500 skilled nursing facilities in the U.S offering longer-term care to patients in need of assistance with the activities of daily life. Approximately 25% of first-time U.S. Medicare heart failure hospital patients are discharged to skilled nursing facilities, up from only 5% thirty years ago. These trends are being driven with the objective of reducing hospital readmissions and combatting chronic heart failure post-acute care costs which can comprise up to 70% of the total cost of care. The SOZO fluid analysis for heart failure is a novel tool for assessing fluid overload in heart failure patients. It utilises ImpediMed's HF-DexTM heart failure index which is a measure of extracellular fluid as a percent of total body water. HF-Dex is presented on reference ranges derived from an analysis of heart failure patients from ImpediMed's heart failure home study and research performed on healthy subjects. The heart failure home study is an observational study that tracks recently hospitalised heart failure patients with daily SOZO tests at home. The analysis yielded BIS-derived reference ranges for normal fluid volumes, elevated fluid volumes, and fluid overload, which is defined as HF-Dex greater than 51%. Data from this study, combined with individual patient case reports illustrates the benefits of SOZO in heart failure patients: Differentiating between fluid and tissue-related weight changes. Tracking response to medication changes. A marker for readmission when HF-Dex is higher than 51%.
お知らせ • Nov 16ImpediMed Limited Announces NSW Health Further Expands Lymphoedema Prevention ProgramImpediMed Limited announced that New South Wales Health is further expanding patient access to its lymphoedema prevention program using the SOZO® Digital Health Platform through the purchase of 25 additional SOZO units. NSW Health is now one of the largest providers of the SOZO Digital Health Platform in Australia, with over 45 units purchased to date. In April of this year, ImpediMed announced the purchase of eight additional SOZO units, with five of these devices deployed in the Western NSW Local Health District (LHD) of NSW Health. Following successful implementation of the program, NSW Health will use the new devices to further expand patient access in both metropolitan and rural areas. NSW Health operates over 230 public hospitals in its eight local districts that cover the Sydney metropolitan region and surrounding rural areas. With nearly 45,000 new cancer cases every year, NSW is the largest public health system in Australia. As a connected health platform, SOZO allows patient's care providers to access their lymphoedema measurements at every location in the NSW Health network. The Lymphoedema Prevention Program utilises ImpediMed's Test, Trigger, TreatTM protocol for early detection and intervention of cancer-related lymphoedema. Routine lymphoedema testing of cancer survivors uses the company's SOZO device with BIS (L-Dex®) technology. A significant increase in a patient's L-Dex score is a trigger to evaluate the patient and initiate intervention. ImpediMed's PREVENT Trial, the largest multi-site, randomised controlled trial ever performed to study lymphoedema prevention, showed that this protocol resulted in a 95% reduction in lymphoedema progression at one year.
お知らせ • Nov 09AstraZeneca Selects SOZO for Second Large Renal TrialImpediMed Limited announced a second contract valued at over $2.0 million for its SOZO® Digital Health Platform to be used in a clinical trial being conducted for AstraZeneca, a global pharmaceutical company. The Phase II trial will use the SOZO devices to track patient fluid volume in an upcoming pharmaceutical study focused on chronic kidney disease. The study, which is scheduled to begin in January 2021 and run for approximately 18 months, will require approximately 200 additional devices globally. The company previously announced in September 2020 that AstraZeneca will use SOZO to track patient fluid volume in a clinical trial focused on heart failure and chronic kidney disease. A combined 375 SOZO devices will now be leased across 31 countries for the two trials. Together, the trials are expected to generate in excess of $4.5 million in revenue. Under the terms of the agreement, and in alignment with the Company's SaaS business model, each device will have a monthly license fee for the duration of the study. ImpediMed will retain ownership of the devices at the conclusion of the trials.
お知らせ • Oct 04HFSA Poster Supports HF-Dex in the Management of HF PatientsImpediMed Limited announced a poster presentation at the prestigious Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting, 30 September 6 October 2020. The poster combines heart failure patient data from ImpediMed's Heart Failure at Home and IMPEL studies. It demonstrates that a SOZO® with HF-DexTM assessment greater than 51% serves as a marker for heart failure hospital readmission. The findings showed a statistically significant (p<0.05) difference in median HF-Dex for patients readmitted for heart failure (52.1%) compared to patients not readmitted for heart failure (49.0%) and healthy subjects (44.8%). The patients with class II or III heart failure underwent BIS measurements in an ambulatory care setting or at home using the SOZO technology. The SOZO HF-Dex Heart Failure (HF) Index, which is extracellular fluid (ECF) as a percentage of total body water (TBW), was evaluated for differences across three groups of individuals: HF patients readmitted for acute heart failure (decompensated), HF patients not readmitted (compensated) and healthy adults aged 40+ years. Results show patients readmitted for acute heart failure had a median ECF%TBW of 52.1% supporting HF-Dex greater than 51% is a marker for readmission. The compensated group had a median ECF%TBW of 49.0%, and the healthy population's median was 44.8%. The SOZO HF-Dex heart failure index is a novel tool for assessing fluid overload in heart failure. Data from this poster, combined with individual patient case reports illustrates additional benefits of SOZO in heart failure patients: Differentiating between fluid and tissue-related weight changes, Tracking response to medication changes, A marker for readmission when HF-Dex is higher than 51%.
お知らせ • Oct 03Impedimed Limited Announces Collaboration with the Live Today Foundation to Increase Awareness and Access to Care for Cancer Patients At Risk or Suffering from LymphedemaImpediMed Limited announced a collaboration with the LIVE Today Foundation. Introduced at the start of Breast Cancer Awareness Month, the partnership involves activities that reflect a joint mission of improving awareness as well as access to care for cancer patients in the U.S. who are at risk of developing lymphedema or are struggling with it. ImpediMed will provide support to the foundation for the purchase and distribution of lymphedema compression garments to underserved patients as well as help to develop and implement educational programs for physicians and patients. Currently, one in three cancer survivors will develop secondary lymphedema related to their cancer treatment, costing the U.S. healthcare system approximately $7 billion every year. In 2019, ImpediMed introduced a comprehensive Lymphedema Prevention Program to help educate healthcare providers and patients that with proper protocols in place, lymphedema can be detected and managed before it becomes a debilitating, chronic condition. This program utilizes ImpediMed's Test, Trigger, Treat™ protocol for early detection and intervention of cancer-related lymphedema. Routine lymphedema testing of cancer survivors uses the company's FDA-cleared SOZO® device with BIS (L-Dex®) technology, which measures extracellular fluid. A significant increase in a patient's L-Dex score is a trigger to evaluate the patient and initiate intervention. ImpediMed's PREVENT Trial demonstrated that routine monitoring with L-Dex combined with at-home intervention resulted in a 95% reduction in lymphedema progression at one year. Today, L-Dex is the only non-invasive, reliable, validated tool to help clinicians identify subclinical lymphedema. The company's SOZO digital health platform can measure a patient's L-Dex score with a simple, painless 30-second scan. Monitoring L-Dex scores allows clinicians across multiple specialties to provide individualized, proactive care that can help improve patient outcomes.
お知らせ • Sep 30Impedimed Limited Announces Contract Valued at over AUD 2 Million for its SOZO Digital Health Platform to Be Used in Clinical Trial Being Conducted for AstraZenecaImpediMed Limited announced a contract valued at over AUD 2 million for its SOZO® Digital Health Platform to be used in a clinical trial being conducted for AstraZeneca. The Phase II trial will use the SOZO devices to track patient fluid volume in an upcoming pharmaceutical study focused on heart failure and chronic kidney disease. The study, which will begin in the second fiscal quarter and run for approximately 18 months, will require approximately 175 devices globally. AstraZeneca has used ImpediMed’s BIS technology for a number of years to measure subjects’ fluid volumes in their clinical studies. With SOZO, they will be able to achieve the fluid measurement accuracy of gold standard dilution methods in a test that takes 30 seconds instead of up to 24 hours. Add in the fact that it offers real-time data review globally, and it’s clear why the SOZO Digital Health Platform was chosen for this new research. The AstraZeneca study using SOZO will evaluate the efficacy, safety, and tolerability of a combination of two AstraZeneca drugs in heart failure patients with chronic kidney disease. This Phase II trial is scheduled to begin in November 2020. The trial is being run by a contract research organization on behalf of AstraZeneca. Under the terms of the agreement, and in alignment with the Company’s SaaS business model, each device will have a monthly license fee for the duration of the study. ImpediMed will retain ownership of the devices at the conclusion of the trials. SOZO is FDA-cleared for heart failure and CE-Marked for heart failure and renal failure. The trial will provide a significant number of cardiologists, both in the US and globally, firsthand experience with SOZO and coincides with ImpediMed’s launch into the cardiology market. Cardiovascular disease is the leading cause of death among those with kidney disease. Among hospitalizations for primary heart failure, one of the most common comorbid diagnoses is chronic kidney disease (47%).
お知らせ • Sep 21ImpediMed Limited(ASX:IPD) dropped from S&P/ASX Emerging Companies IndexImpediMed Limited(ASX:IPD) dropped from S&P/ASX Emerging Companies Index
お知らせ • Sep 01ImpediMed Limited Auditor Raises 'Going Concern' DoubtImpediMed Limited filed its Annual on Aug 25, 2020 for the period ending Jun 30, 2020. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
お知らせ • Jul 21ImpediMed Limited to Report Q4, 2020 Results on Jul 28, 2020ImpediMed Limited announced that they will report Q4, 2020 results at 9:21 PM, GMT Standard Time on Jul 28, 2020
お知らせ • Jul 07ImpediMed Limited announced that it has received AUD 0.227339 million in fundingImpediMed Limited (ASX:IPD) announced a private placement of 3,444,527 ordinary shares at a price of AUD 0.066 per share for the gross proceeds of AUD 227338.782 on July 1, 2020. The transaction will include participation from executives and nonexecutive directors of the company. The transaction has been approved by the shareholders of the company at annual general meeting.